XHS Quote, Financials, Valuation and Earnings

Range Cancer Therapeutics ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat Range Cancer Therapeutics ETF's return on equity of --.

SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Range Cancer Therapeutics ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than Range Cancer Therapeutics ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than Range Cancer Therapeutics ETF.

SPDR S&P Health Care Services ETF has a beta of 1.045, which suggesting that the stock is 4.477% more volatile than S&P 500. In comparison Range Cancer Therapeutics ETF has a beta of 1.110, suggesting its more volatile than the S&P 500 by 10.972%.

SPDR S&P Health Care Services ETF has a quarterly dividend of $0.04 per share corresponding to a yield of 0.35%. Range Cancer Therapeutics ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. Range Cancer Therapeutics ETF pays out -- of its earnings as a dividend.

SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than Range Cancer Therapeutics ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than Range Cancer Therapeutics ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while Range Cancer Therapeutics ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for Range Cancer Therapeutics ETF. Usually stocks with elevated PS ratios are considered overvalued.

First Trust Nasdaq Pharmaceuticals ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat First Trust Nasdaq Pharmaceuticals ETF's return on equity of --.

SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than First Trust Nasdaq Pharmaceuticals ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than First Trust Nasdaq Pharmaceuticals ETF.

SPDR S&P Health Care Services ETF has a beta of 1.045, which suggesting that the stock is 4.477% more volatile than S&P 500. In comparison First Trust Nasdaq Pharmaceuticals ETF has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.143%.

SPDR S&P Health Care Services ETF has a quarterly dividend of $0.04 per share corresponding to a yield of 0.35%. First Trust Nasdaq Pharmaceuticals ETF offers a yield of 1.93% to investors and pays a quarterly dividend of $0.12 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. First Trust Nasdaq Pharmaceuticals ETF pays out -- of its earnings as a dividend.

SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Pharmaceuticals ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than First Trust Nasdaq Pharmaceuticals ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while First Trust Nasdaq Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for First Trust Nasdaq Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.

ALPS Medical Breakthroughs ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat ALPS Medical Breakthroughs ETF's return on equity of --.

SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ALPS Medical Breakthroughs ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than ALPS Medical Breakthroughs ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than ALPS Medical Breakthroughs ETF.

SPDR S&P Health Care Services ETF has a beta of 1.045, which suggesting that the stock is 4.477% more volatile than S&P 500. In comparison ALPS Medical Breakthroughs ETF has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.647%.

SPDR S&P Health Care Services ETF has a quarterly dividend of $0.04 per share corresponding to a yield of 0.35%. ALPS Medical Breakthroughs ETF offers a yield of 4.26% to investors and pays a quarterly dividend of $1.17 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. ALPS Medical Breakthroughs ETF pays out -- of its earnings as a dividend.

SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than ALPS Medical Breakthroughs ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than ALPS Medical Breakthroughs ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while ALPS Medical Breakthroughs ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for ALPS Medical Breakthroughs ETF. Usually stocks with elevated PS ratios are considered overvalued.

SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat SPDR S&P Pharmaceuticals ETF's return on equity of --.

SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than SPDR S&P Pharmaceuticals ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than SPDR S&P Pharmaceuticals ETF.

SPDR S&P Health Care Services ETF has a beta of 1.045, which suggesting that the stock is 4.477% more volatile than S&P 500. In comparison SPDR S&P Pharmaceuticals ETF has a beta of 0.715, suggesting its less volatile than the S&P 500 by 28.453%.

SPDR S&P Health Care Services ETF has a quarterly dividend of $0.04 per share corresponding to a yield of 0.35%. SPDR S&P Pharmaceuticals ETF offers a yield of 1.69% to investors and pays a quarterly dividend of $0.15 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.

SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than SPDR S&P Pharmaceuticals ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than SPDR S&P Pharmaceuticals ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.